Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in other brain neurons (168 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 8356
Sealed predictions
- CTIF in dopamine neurons, braak-0.30 (p 0.428) → -0.28 (p 0.473)receipt 8363
Swarm cases
receipt 8363: CTIF in dopamine neurons, braak
- power
- full sample -0.28 (p 0.265, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.265, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.037, n 18). not the mix.
- skeptic
- leave-one-out range -0.38 to -0.18, sign flips 0; without severely affected donors -0.28 (p 0.265, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.59 (p 0.0096, n 18) vs -0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CTIF in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CTIF · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.07 p 0.790 (needs p < 2.5e-4)
Receipts
loading the receipts